Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/107084
Title: Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II
Authors: Vieira, Raquel 
Souto, Selma B.
Sánchez-López, Elena 
Machado, Ana López
Severino, Patrícia 
Jose, Sajan
Santini, Antonello
Fortuna, Ana 
García, Maria Luisa
Souto, Eliana B. 
Keywords: diabetes mellitus; animal models; in vivo; administration routes
Issue Date: 28-Aug-2019
Publisher: MDPI
Project: M-ERA-NET/0004/2015-PAIRED 
Institute of Nanoscience and Nanotechnology under the project ART (2018) 
metadata.degois.publication.title: Journal of Clinical Medicine
metadata.degois.publication.volume: 8
metadata.degois.publication.issue: 9
Abstract: Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.
URI: https://hdl.handle.net/10316/107084
ISSN: 2077-0383
DOI: 10.3390/jcm8091332
Rights: openAccess
Appears in Collections:FFUC- Artigos em Revistas Internacionais

Show full item record

SCOPUSTM   
Citations

52
checked on Nov 4, 2024

WEB OF SCIENCETM
Citations

44
checked on Nov 2, 2024

Page view(s)

92
checked on Nov 5, 2024

Download(s)

37
checked on Nov 5, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons